Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Director Henry Scott Robert of Nexgel, Inc. (NASDAQ:NXGL), a micro-cap company with a market value of $19.36 million, sold 7,697 shares of common stock on September 25, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $2.3579, realizing total proceeds of $18,148. The transaction comes as the stock has declined 45.63% year-to-date, according to InvestingPro data.
The sales were executed in multiple transactions at prices ranging from $2.3500 to $2.3900 per share. Following the transaction, Robert directly owns 121,356 shares of Nexgel . Despite challenging market conditions, the company has achieved impressive revenue growth of 133% over the last twelve months, though InvestingPro analysis indicates the company is currently burning through cash.
The sale was conducted under a Rule 10b5-1 trading plan. For deeper insights into NXGL’s financial health and additional exclusive tips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Nexgel Inc reported its second-quarter 2025 earnings, showcasing a significant revenue increase of 100% year-over-year to $2.9 million. However, this figure fell short of the analysts’ forecast of $3.08 million. The company’s earnings per share (EPS) were reported at -$0.09, missing the expected -$0.05. Despite these results, Nexgel’s stock remained stable. The company emphasized its ongoing focus on innovation and expansion, particularly noting growth in its contract manufacturing and consumer products segments. These developments highlight Nexgel’s strategic efforts to enhance its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.